ArticleBlood research2026
Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effectiveness, treatment durability, and infectious complications of frontline daratumumab, lenalidomide, and dexamethasone (DRd) in patients aged > 80 years with transplant-ineligible newly diagnosed multiple myeloma (Ti-NDMM) and to explore associations between baseline nutritional vulnerability and treatment outcomes.
methodsWe retrospectively analyzed consecutive patients aged > 80 years with Ti-NDMM who received frontline DRd. Treatment outcomes and infectious complications were also evaluated. Exploratory analyses were performed according to baseline nutritional indices, including the Prognostic Nutritional Index (PNI) and Geriatric Nutritional Risk Index.
resultsFifteen patients were included. The overall response rate was 93.3%, and 53.3% of patients achieved a very good partial response or better. After a median follow-up of 23.1 months, the estimated median duration of treatment (DOT), time to the next treatment, and progression-free survival (PFS) were 36.7, 44.6, and 40.0 months, respectively, while the estimated median overall survival was not reached. Infectious complications, including two infection-related deaths, represented a major barrier to treatment continuation. Severe infections predominantly occurred within the first year of treatment initiation. In exploratory analyses, patients with a low baseline PNI had a shorter DOT (30.8 months vs. not reached; p = 0.049) and more frequent grade 3-5 infections (71.4% vs. 12.5%; p = 0.041).
conclusionFrontline DRd demonstrated favorable effectiveness and clinically meaningful treatment durability in patients aged > 80 years with Ti-NDMM. Infectious complications, particularly during the early treatment period, frequently compromised the continuation of treatment. Exploratory analyses suggested that a lower baseline PNI may be associated with severe infectious complications and a shorter treatment durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.